MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal® G4 HIV-1/2 rapid test for VA, Department of Defence

Halifax, Nova Scotia, 17th of April, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira’s Service-Disabled Veteran-Owned […]
MedMira Announces Partnership with MediGroup Physician Services in the United States

Halifax, Nova Scotia, 27th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new partnership allows the Company to promote and sell its products to over 44,000 existing customers. MediGroup is the United States’s largest group purchasing organisations […]
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada

Halifax, Nova Scotia, 25th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership allows MedMira to expedite its growth in the Canadian market with the recently Health Canada approved Multiplo® TP/HIV rapid antibody test and its Reveal® G4 HIV-1/2 rapid […]
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number 11,353,450) received in 2022. Through this new patent, MedMira is to further diversify its patent portfolio […]